Bristol-Myers Squibb Says Camzyos Shows Sustained Efficacy in Phase 3 Pediatric Trial

04:56 PM EST, 11/06/2026 (MT Newswires) -- Bristol-Myers Squibb (BMY) said late Friday that 56-week results from its Phase 3 SCOUT-HCM clinical trial showed sustained efficacy and a consistent safety profile for Camzyos, or mavacamten in pediatric patients aged 12 to 17 with symptomatic obstructive hypertrophic cardiomyopathy. The results were consistent with previously reported 28-week findings, with patients in both treatment groups achieving significant reductions in left ventricular outflow tract gradients, a measure of obstruction to blood flow from the heart, the company said. Patients who received Camzyos throughout the study experienced a mean reduction of 48.1 mmHg from baseline after 56 weeks, while those who switched from placebo to Camzyos at week 28 showed similar improvements. Both groups also demonstrated meaningful improvements in several secondary endpoints, with no new safety signals reported, the company said. Camzyos received US Food and Drug Administration approval in September for pediatric patients weighing at least 30 kilograms, or 66 pounds, with symptomatic obstructive hypertrophic cardiomyopathy, Bristol-Myers Squibb said.